Clene (NASDAQ:CLNN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Clene (NASDAQ:CLNN) in a report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $23.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Clene to a “strong-buy” rating in a report on Tuesday, September 10th. Canaccord Genuity Group reduced their target price on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $31.00 price target on shares of Clene in a research note on Thursday, November 14th. Finally, Benchmark reduced their price objective on shares of Clene from $90.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Clene presently has an average rating of “Buy” and an average target price of $55.25.

Clene Stock Up 3.8 %

NASDAQ:CLNN opened at $4.93 on Tuesday. The company has a market cap of $41.21 million, a price-to-earnings ratio of -0.93 and a beta of 0.33. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.82 and a current ratio of 0.83. The stock’s fifty day moving average price is $5.09 and its two-hundred day moving average price is $5.57. Clene has a 52-week low of $3.82 and a 52-week high of $12.00.

Insider Buying and Selling

In other news, insider Mark Mortenson purchased 20,512 shares of Clene stock in a transaction dated Monday, September 30th. The shares were bought at an average cost of $4.75 per share, with a total value of $97,432.00. Following the completion of the transaction, the insider now directly owns 28,949 shares in the company, valued at $137,507.75. This trade represents a 243.12 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David J. Matlin purchased 92,307 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $4.75 per share, with a total value of $438,458.25. Following the acquisition, the director now directly owns 444,491 shares in the company, valued at $2,111,332.25. This trade represents a 26.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 25.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Clene

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC bought a new position in shares of Clene Inc. (NASDAQ:CLNN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned 0.19% of Clene as of its most recent filing with the SEC. 23.28% of the stock is currently owned by hedge funds and other institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.